Silencing of NLRP3 Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin

Figure 1

NLRP3 is overexpressed in ovarian cancer and linked to poor prognosis. (a) The gene expression data for ovarian cancer patients with NLRP3 expression information (GSE26712, GSE53963, GSE51088, GSE66957, and GSE135886) were obtained from the NCBI GEO database. (b) The expression profile of NLRP3 in ovarian cancer from TCGA database. (c) NLRP3 level in different clinical stages of patients with ovarian cancer. (d) The survival rate analysis of NLRP3 level and ovarian cancer patients. (e) Cox regression analysis of NLRP3 in ovarian cancer. (f) TIMER database was adopted to assess the association between NLRP3 level and immune infiltrates’ abundances in ovarian cancer.

(a)

(b)

(c)

(d)

(e)

(f)